# Cellshoot Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellshoot-therapeutics

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.cellshoot.co.jp
- Total disclosed funding: $1.7M
- Latest round: Seed (Aug 1, 2022)
- Investors on record: 3

## About

Based in Tokyo, Japan, and founded in 2021 by CEO Jie Zhang, Ph.D., and co-founder Liangfang Zhang, Ph.D., Cellshoot Therapeutics, Inc. operates as a pharmaceutical research company, providing drug discovery target molecules and creating drug candidates by utilising the technology of intracellular protein pathway analysis. In August 2022, Cellshoot Therapeutics, Inc. raised JPY 230 million in seed funding from Kyoto University Innovation Capital, SMBC Venture Capital, and Fast Track Initiative.

Cellshoot Therapeutics provides protein localization and the modification-based covariation network analysis method (PLOM-CON) for extracting and analysing the quantity and quality of proteins from fluorescent antibody-producing cells. The company provides a semi-intact cell sealing method in which molecules are introduced from outside the cells and then into the cells. As of 2023, the company serves industries such as pharmaceuticals, medicine development, and research and development.

## Funding rounds

- Seed, Aug 1, 2022, $1.7M — SMBC Venture Capital, Fast Track Initiative, Kyoto University Innovation Capital

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Seed
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Seed
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed